The goal of this project is to develop an early diagnostic test for Alzheimer's disease (AD). Neuropathology studies show, in mild cognitive impairment (MCI) and some normal (NL) elderly, neurofibrillary and plaque pathology that is associated with neuronal and volume losses in the entorhinal cortex (EC) and hippocampus. Our prior work shows that MRI volume reductions in these regions predict future MCI and AD. However, volume losses lack disease specificity. Together, our most recent publication and those of our collaborators show that tangle-related abnormal tau proteins, hyperphosphorylated at threonine 231 (P-tau231), are: 1) elevated in the CSF in MCI and AD; 2) diagnostically specific for AD; 3) useful in predicting further cognitive decline in MCI; and 4) diluted in the CSF by the progressive ventricular enlargement of AD, such that CSF volume adjustment enables detection of longitudinal P-tau231 increases in MCI. Our pilot data demonstrates that P-tau231 significantly adds to the MRI hippocampal volume in the classification of MCI and NL. A-beta40 levels are also elevated in MCI. Overall, these findings suggest that by combining the sensitivity of the MRI hippocampal volume with the specificity of CSF P-tau231, a sensitive and specific in vivo recognition of AD pathology in MCI is possible. We propose the longitudinal study of 30 NL, 80 MCI, 30 mild AD, and 30 frontotemporal dementia (FTD) patients. Over 5-years, we will complete baseline and 24-month follow-up exams. We will use standardized clinical protocols at each observation and collect normreferenced neuropsychological data, high-resolution MRI, and CSF. We hypothesize that elevated Ptau231 is specific for AD, and that it independently contributes to the hippocampal volume in both the differential diagnosis of AD, and in predicting the MCI conversion to AD. All the required clinical components, laboratory, and imaging for this study are in place with established quality control. There are ample numbers of volunteer subjects and patients available. There is adequate statistical power for testing the hypotheses.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
2R01AG012101-11
Application #
6684867
Study Section
Special Emphasis Panel (ZRG1-BDCN-6 (01))
Program Officer
Buckholtz, Neil
Project Start
1993-09-30
Project End
2008-08-31
Budget Start
2003-09-30
Budget End
2004-08-31
Support Year
11
Fiscal Year
2003
Total Cost
$356,685
Indirect Cost
Name
New York University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Butler, Tracy; Harvey, Patrick; Deshpande, Anup et al. (2018) Basal forebrain septal nuclei are enlarged in healthy subjects prior to the development of Alzheimer's disease. Neurobiol Aging 65:201-205
Snyder, Heather M; Carare, Roxana O; DeKosky, Steven T et al. (2018) Military-related risk factors for dementia. Alzheimers Dement 14:1651-1662
Illán-Gala, Ignacio; Pegueroles, Jordi; Montal, Victor et al. (2018) Challenges associated with biomarker-based classification systems for Alzheimer's disease. Alzheimers Dement (Amst) 10:346-357
Ramos-Cejudo, Jaime; Wisniewski, Thomas; Marmar, Charles et al. (2018) Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. EBioMedicine 28:21-30
Lewczuk, Piotr; Riederer, Peter; O'Bryant, Sid E et al. (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 19:244-328
Chen, Jingyun; Li, Yi; Pirraglia, Elizabeth et al. (2018) Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization. Eur J Nucl Med Mol Imaging 45:1596-1604
de Leon, Mony J; Li, Yi; Rusinek, Henry (2018) Reply: Cerebrospinal Fluid, Hyposmia, and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. J Nucl Med 59:718-719
Mattsson, Niklas; Groot, Colin; Jansen, Willemijn J et al. (2018) Prevalence of the apolipoprotein E ?4 allele in amyloid ? positive subjects across the spectrum of Alzheimer's disease. Alzheimers Dement 14:913-924
Fortea, Juan; Carmona-Iragui, María; Benejam, Bessy et al. (2018) Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol 17:860-869
Sharma, Ram A; Varga, Andrew W; Bubu, Omonigho M et al. (2018) Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. Am J Respir Crit Care Med 197:933-943

Showing the most recent 10 out of 183 publications